Cart is emptyNeuroblastoma Risk Stratification Tool
This tool helps clinicians assess risk stratification in neuroblastoma patients based on established clinical parameters and biomarkers
Demographics
Tumor Characteristics
Clinical Presentation
Risk Stratification Result
Interpretation
Based on the provided clinical and biological parameters, this patient falls into the Low Risk category for neuroblastoma.
Risk Category Explanation:
- Low Risk: Estimated 5-year survival >95% with surgery alone or minimal chemotherapy
- Intermediate Risk: Estimated 5-year survival 90-95% with moderate chemotherapy
- High Risk: Estimated 5-year survival 50-60% with intensive multimodal therapy
Recommended Actions:
- Complete surgical resection if possible
- Observation for selected patients with stage 1 disease
- Chemotherapy only for symptomatic patients or those with impending complications
- Regular follow-up with imaging and tumor marker surveillance
Try More Free Tools:
- Try Our Do I Have Mesothelioma? Free Quiz For Early Diagnosis
- Try Our Mesothelioma Risk Calculator
- Try Our Pediatric Leukemia Risk Calculator
Neuroblastoma Risk Stratification Tool
Table Of Contents
What is Neuroblastoma?
Neuroblastoma is a pediatric cancer that develops from immature nerve cells, primarily affecting infants and young children. It is the most common extracranial solid tumor in childhood, accounting for about 6-10% of all pediatric cancers.
This aggressive cancer typically arises in the adrenal glands but can also form along the sympathetic nervous system (abdomen, chest, neck, or pelvis). Due to its heterogeneous nature, neuroblastoma prognosis varies widely—some cases spontaneously regress, while others progress aggressively.
Why is the Neuroblastoma Risk Stratification Tool Important?
Risk stratification helps oncologists determine:
- Disease severity (low, intermediate, or high risk)
- Optimal treatment approach (surgery, chemotherapy, immunotherapy, or radiation)
- Prognosis and survival rates
Our free Neuroblastoma Risk Stratification Tool simplifies this assessment by analyzing clinical, genetic, and pathological factors to provide a personalized risk score.
Key Factors in Neuroblastoma Risk Stratification Tool
1. Patient Demographics
- Age at Diagnosis (<18 months = better prognosis)
- Gender (slight male predominance)
2. Tumor Characteristics
- Primary Tumor Site (adrenal vs. non-adrenal)
- Tumor Size (larger tumors = higher risk)
- INSS Stage (International Neuroblastoma Staging System)
- Stage 1-2: Localized
- Stage 3: Locally invasive
- Stage 4: Metastatic
- Stage 4S: Special category (<1 year with limited spread)
3. Histopathology & Biology
- Shimada Classification (favorable vs. unfavorable histology)
- Mitosis-Karyorrhexis Index (MKI) (measures cell division rate)
- MYCN Amplification (oncogene linked to aggressive disease)
- DNA Ploidy (hyperdiploid = better prognosis)
- Chromosomal Abnormalities (1p deletion, 11q aberration = worse outcomes)
4. Tumor Markers & Metastasis
- Serum LDH & Ferritin (elevated levels = poor prognosis)
- Bone Marrow Involvement (indicates advanced disease)
- Bone/Liver Metastases (higher risk in Stage 4)
How the Neuroblastoma Risk Stratification Tool Works
Our tool evaluates clinical inputs to generate a risk score categorized as:
| Risk Category | 5-Year Survival Rate | Treatment Approach |
|---|---|---|
| Low Risk | >95% | Surgery ± minimal chemo |
| Intermediate Risk | 80-95% | Moderate chemo + surgery |
| High Risk | <50% | Intensive chemo, immunotherapy, stem cell transplant |
Step-by-Step Process
- Enter patient demographics (age, gender).
- Input tumor details (size, stage, location).
- Provide histopathology & genetic data (MYCN, ploidy).
- Get instant risk stratification with color-coded results.
- Download a PDF report for medical records.
Understanding Your Neuroblastoma Risk Results
1. Low Risk (Green Zone)
- Characteristics: Localized tumor, favorable biology, no MYCN amplification.
- Treatment: Surgery alone or with minimal chemotherapy.
- Prognosis: Excellent (>95% survival).
2. Intermediate Risk (Yellow Zone)
- Characteristics: Regional spread, possible unfavorable histology.
- Treatment: Multi-agent chemotherapy + delayed surgery.
- Prognosis: Good (80-95% survival).
3. High Risk (Red Zone)
- Characteristics: Metastatic disease, MYCN amplification, unfavorable markers.
- Treatment: Aggressive chemo, stem cell transplant, immunotherapy.
- Prognosis: Poor (<50% survival).
Why Use Our Neuroblastoma Risk Calculator?
✅ Evidence-based scoring (aligned with COG & SIOP protocols)
✅ Instant risk assessment (no manual calculations)
✅ Personalized PDF report (for doctors & caregivers)
✅ Free & easy-to-use (no registration required
Final Thoughts
Early risk stratification is crucial for personalized neuroblastoma treatment. Our free calculator helps parents and doctors assess prognosis quickly and accurately.
🔗 Try the Neuroblastoma Risk Stratification Tool now!
FAQs
What is the most important factor in neuroblastoma prognosis?
MYCN amplification is the strongest predictor of poor outcomes.
Can neuroblastoma be cured?
Low-risk cases have high cure rates, while high-risk cases require intensive therapy.
How accurate is this calculator?
It follows international guidelines (COG, INRG) but should complement doctor consultations.
Add a Comment